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Abstract
Background: Multiple sclerosis (MS) is an autoimmune disorder characterized by chronic inflammation,
demyelination, and neuronal damage. During autoimmunity, cytokines are important mediators of the
inflammation. In this line, interleukin-27 (IL-27) modulates inflammation and can be produced directly at
inflammatory sites such as in the joints during rheumatoid arthritis or in the central nervous system (CNS)
during MS. While in animal models of MS, treatment with IL-27 decreases the disease severity, its role in
humans is not clearly established and it is not known if IL-27 could be detected in the cerebrospinal fluid
(CSF) of MS patients.
Methods: In this study, we measured IL-27 levels using a quantitative enzyme-linked immunosorbent assay in CSF of
patients with relapsing remitting multiple sclerosis (RRMS), isolated optic neuritis (ON) and non-inflammatory
neurological disease (NIND) as well as in the sera of healthy donors (HD) and RRMS patients undergoing different
disease modifying treatments. We further confirmed by immunohistology of patient biopsies the identity of IL-27
producing cells in the brain of active MS lesions.
Results: We observed that IL-27 levels are increased in the CSF but not in the sera of RRMS compared to HD. We
confirmed that IL-27 is expressed in active MS plaques by astrocytes of MS patients.
Conclusions: Our results point toward a local secretion of IL-27 in the CNS that is increased during autoimmune
processes. We propose that local production of IL-27 could sign the induction of a regulatory response that promotes
inflammation’s resolution. The effect of new immunomodulatory therapies on cerebral IL-27 production could be used
to understand the biology of IL-27 in MS disease.
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Background
Multiple sclerosis (MS) is an autoimmune disorder char-
acterized by demyelination, chronic inflammation, and
neuronal damage. Among mediators recognized to con-
tribute to inflammatory processes in the CNS, accumu-
lating evidence indicates that members of interleukin-12
(IL-12) family of cytokines, which includes IL-12, IL-23,
IL-35, and IL-27, are important mediators of inflamma-
tion. While IL-12 and IL-23 have clearly been demon-
strated to be pro-inflammatory, IL-27 has been ascribed
with additional anti-inflammatory properties. In this line,
continuous infusion of IL-27 has been shown to dampen
disease severity during the experimental autoimmune
encephalomyelitis (EAE), an animal model for MS [1–3].
In addition, mice that lack the receptor for IL-27 or IL-27-
downstream signaling transcription factors are character-
ized by more severe EAE disease compared to control
mice [4, 5]. Translational human studies performed in
vitro indicate that IL-27 secretion from dendritic cells
(DCs) obtained from healthy donors can increase upon
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exposure to the drug-modifying treatment IFN-β. Further,
in vitro analysis proposed IL-27 as a marker to identify
responders to IFN-β treatment [6] as IL-27 secretion was
increased from ex vivo isolated plasmacytoid dendritic
cells (pDCs) from MS patients treated with IFN-β for
1 month [7]. In this line, elevation of IL-27 has been ob-
served in patients responding to glatiramer acetate therapy
[8]. Those studies all point toward an anti-inflammatory
function of IL-27 during CNS autoimmunity.
In addition to IL-27 secretion in the immune peripheral
compartment, IL-27 can be produced directly at the sites
of inflammation by local resident cells and antigen
presenting cells (APC). In rheumatoid arthritis, in-
creased IL-27 levels in the joint synovial fluid but not
in the blood have been reported [9]. Furthermore, IL-27
can be secreted by resident cells of the CNS such as astro-
cytes or microglia cultured in vitro [10, 11]. IL-27 was
shown to be expressed in astrocytes and microglia in MS
brains [12]. However, it is not known if IL-27 could be de-
tected directly in the CSF of RRMS patients. We here
show that IL-27 production from the CNS can be directly
assessed in CSF and in addition that it is increased in
RRMS compared to other non-inflammatory neurological
diseases or healthy controls. We further confirm that IL-
27 is expressed in astrocytes from brain biopsies of MS
patients presenting with active lesions.
Methods
CSF and sera
Cerebrospinal fluids (CSF), collected in excess during
spinal taps performed for diagnosis purposes, were stored
anonymously in a centralized biobank for retrospective re-
search purposes. This research was conducted according
to the regulations of the Act on Medical Research Involv-
ing Human Subjects of the Geneva University Hospital
(HUGO.RE.DG.0010). This study was approved by The
Geneva University Hospital Medical Ethical board
(Authorization # 07-261R (NAC 07-102R).
The three CSF groups tested were composed of
relapsing remitting multiple sclerosis (RRMS), isolated
optic neuritis (ON), and non-inflammatory neurological
diseases (NIND). NIND consisted of patients who
underwent spinal tap for investigation of peripheral
seventh nerve palsy or of headaches, which revealed
to be non-inflammatory. For RRMS patients, the re-
vised 2005 McDonald Criteria [13] were used to
diagnose MS. Demographic and clinical characteris-
tics, including gender, age, neurological symptoms
and signs, and CSF white blood cell (WBC) count
were retrieved from our CSF biobank database as
previously described [14].
Sera were collected from healthy controls (HC) and
RRMS patients under different disease-modifying
treatments.
Analysis of IL-27 in the sera and CSF
IL-27 was measured using an enzyme immune-assay
(Human IL-27 ELISA, Kit: Duo Set (R&D) Ref:DY2526).
EBI3 immunohistochemistry
Post-mortem samples and biopsies from the human MS
brain were assessed. Formalin-fixed paraffin-embedded
tissue was cut in 2-μm-thick sections. Sections were
dewaxed, rehydrated, and subjected to antigen retrieval
by heat pre-treatment using citrate buffer pH 6. Ebi3
antibody (clone 2G4H6, mouse monoclonal antibody
IgG2a) was diluted 1:500 if visualized using EnVision+
kit (DAKO) or 1:200 together with AffiniPure Goat Anti-
Mouse IgG (H+L) AlexaFluor488 labeled antibody (Jackson
Immunoresearch) for immunofluorescence. GFAP (DAKO,
Z0334, rabbit) antibodies were directly labeled with Alexa-
Fluor555 or AlexaFluor647 following the protocol of the
antibody labeling kit (Invitrogen) and applied 1:100. Nuclei
were counterstained by H&E for brightfield or by DAPI for
fluorescence. Slides were acquired using the Panoramic 250
Flash II (3D-Histech) slide scanner.
Statistical analysis
Differences in variables were analyzed using ANOVA
and Student’s t tests (for normally distributed data) or
Kruskal–Wallis and Mann–Whitney U tests (for non-
normally distributed data) as appropriate.
Results
Increased production of IL-27 in CSF during RRMS is
correlated with disease activity
Astrocytes have recently been proposed as a source of
IL-27 secretion in active MS lesions [12], which would
suggest that IL-27 is directly produced at the site of
inflammation in the central nervous system. We there-
fore examined IL-27 secretion in CSF. Using the ELISA
that specifically detects the cytokine IL-27, CSF concen-
trations of IL-27 were measured in untreated patients
with RRMS (n = 56), with ON (n = 29), or with NIND
(n = 42) (Fig. 1). The demographic feature characteristics
of patients are shown in Table 1. NIND consisted of
patients who underwent spinal tap for investigation of
peripheral seventh nerve palsy (n = 13) or of headaches
(n = 29), which revealed to be non-infectious and non-
inflammatory.
Our results indicate a higher production of IL-27 in
the CSF of RRMS patients compared to isolated ON and
NIND (p < 0.005) (Fig. 1a). The spinal tap was per-
formed at the time of diagnosis; therefore, none of the
patients were under a disease-modifying treatment and
only two patients had received corticoid treatment. The
levels of IL-27 for those two patients were in the range
of the other values.
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Significant correlation between IL-27 levels and
WBC counts (Fig. 1b) but not with protein levels
(Fig. 1c) were observed in the CSF of RRMS patients.
Those results indicate a link between CNS inflammation
and a local IL-27 secretion and argue against increased
CSF IL-27 levels through blood-brain-barrier (BBB) leak-
age. The CSF levels of IL-27 were correlated to neither
disease severity as indicated by the EDSS score (Fig. 1d)
nor gender (Fig. 1e) nor age (Fig. 1f).
IL-27 CSF levels are correlated to oligoclonal bands
positivity
The correlation between inflammatory parameters and
IL-27 levels prompted us to further look at the correl-
ation between oligoclonal IgG bands (OB) profile in the
CSF and IL-27 levels. OB accompany CNS inflammation
and are found in 95% of patients with MS. Interestingly,
IL-27 CSF levels were lower in the few RRMS patients
that did not present OB positivity (Fig. 2a). Those results
lead us to explore the correlation between OB and IL-27
levels in ON patients. Although IL-27 levels were not
elevated in ON patients compared to HC, ON patients
with a positive OB pattern (that are at higher risk to de-
velop MS) showed significant higher levels of IL-27
compared with ON patients with a negative OB pattern
(Fig. 2b). Similar to RRMS patients, we noted in the CSF
of ON patients a significant correlation between IL-27
levels and WBC (Fig. 2c), but not with protein levels
(data not shown).
No significant change in IL-27 expression in the sera of
RRMS-treated patients
In order to assess if the protein levels of IL-27 were in-
creased in the immune peripheral compartment, IL-27
levels were measured by ELISA in the sera of HC donors
(n = 23) and RRMS patients without treatment (n = 30)
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Fig. 1 Distribution of CSF IL-27 levels in patient subgroups. a The CSF IL-27 levels of all individual patients were measured using quantitative ELISA.
Data are expressed in pg/mL. Only significant p values are shown in the graph (p < 0.001; Kruskal–Wallis test). ON optic neuritis, RRMS relapsing
remitting multiple sclerosis, NIND non-inflammatory neurological diseases. Correlation between IL-27 and b white blood cells counts, c total
proteins levels in the CSF, d EDSS score, e gender, and f age. Pearson product-moment correlation coefficients (r) and p values are shown
Table 1 Demographic and clinical characteristics of patients
(CSF samples n = 127)
NIND (n = 42) ON (n = 29) RRMS (n = 56)
Age (years), mean (±SD) 38.38 (±13.42) 33.03 (±11.72) 34.7 (±9.994)
Gender
Women 20 (48%) 23 (80%) 35 (62.5%)
Men 22 (52%) 6 (20%) 21 (37.5%)
EDSS, mean – – 2.895 (±1.485)
Treatments
DMT – 0 0
Corticoids – 0 2 (3.5%)
NIND non inflammatory neurological disease, ON optic neuritis, RRMS relapsing
remitting multiple sclerosis, EDSS expanded disability status scale, DMT
disease-modifying treatments
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or treated with Interferon beta (IFN-β1a, n = 28), glatira-
mer acetate (GA, n = 24), or natalizumab (NTZ, n = 12).
The demographic features and clinical characteristics of
patients are shown in Table 2. By contrast to the CSF,
IL-27 sera levels of RRMS patients were equivalent to
those observed in HC and were not significantly influ-
enced by disease-modifying treatments (Fig. 3).
IL-27 is expressed in the MS brain by astrocytes
We next investigated if IL-27 could be detected in human
MS lesions similarly as has been previously described in
autopsy MS lesions [12]. First, we assessed IL-27 expres-
sion by bright field immunohistochemistry using an anti-
body directed against EBI3 (a subunit of IL-27) on an
autopsy MS lesion showing a hypocellular center and a
more hypercellular rim (referred to as chronic-active
lesion stage according to [15]). EBI3 immunoreactivity
was mostly observed at the rim of the demyelinated lesion
(Fig. 4a). At higher magnification, the morphology of
EBI3 positive cells resembled astrocytes (Fig. 4b) which
was further confirmed by fluorescence co-staining for
EBI3 together with astrocyte specific marker GFAP
(data not shown).
The notion that EBI3 immunoreactivity was promin-
ent in more active lesion areas together with the obser-
vation that IL-27 expression was noted at high levels in
the CSF at early stages of the disease prompted us to
investigate EBI3 expression in histopathological early
active lesion stages in MS biopsies [16, 17]. We focused
here on pattern II early active MS lesion in biopsies, as
described previously [18], derived from patients with
relatively short disease duration with a mean duration of
5 years (±2.5 years) (Table 3). In these biopsies, we could
detect EBI3 signal (although at variable intensity) that
mostly co-localized with GFAP-expressing astrocytes in
five out of six analyzed lesions (Table 3), one example
being shown in Fig. 4c. Altogether these analyses suggest
that astrocytes may represent the main cellular source
of IL-27 in MS lesions which is in line with previous
observations [12].
Discussion
This study shows that patients suffering from RRMS
exhibit increased IL-27 expression solely in the CNS
compartment as its levels were increased in RRMS
patients compared to controls in CSF but not in sera.
Interestingly, IL-27 was positively correlated with in-
flammatory markers in particular white blood cell count
and OB positivity. The observation that IL-27 positively
correlated with OB in ON patients points toward a role
for IL-27 in early inflammation. Biochemical changes of
the CSF compartment can be considered as a marker of
the CNS inflammation due to its anatomical contact
with the brain interstitial fluid. This corroborates with
immunohistochemistry staining on cerebral MS biopsies
of early active lesions, where astrocytes are found at the
highest level. This is in agreement with CSF analysis and
highlights a local secretion of IL-27 within the CNS
during early neuroinflammation.
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Fig. 2 Distribution of CSF IL-27 levels is correlated with positivity in oligoclonal IgG bands (OB). CSF IL-27 levels and OB pattern in a RRMS and b
ON individual patients. c Correlation between IL-27 and white blood cells counts in ON patients
Table 2 Demographic characteristics of patients for serum analysis
CTRL
(n = 20)
Untreated
(n = 22)
IFN-1a
(n = 21)
GA
(n = 24)
NTZ
(n = 12)
Age, mean ± SEM 39.25 ± 0.5 35.05 ± 0.33 44.05 ± 0.43 37.05 ± 0.49 38.92 ± 0.75
Sex (men/women) 6/14 8/14 3/18 6/18 4/8
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IL-27 has been assigned with both pro- and anti-
inflammatory functions [19]. The increased levels of IL-27
in the CSF that we observe in RRMS patient could either
indicate that IL-27 is implicated in the causality of the dis-
ease with a pro-inflammatory role, or in opposition be
regarded as a secondary host response that would be held
to fight an ongoing disease. We are in favor of a regulatory
role of IL-27, in line with murine models. Our observa-
tions that higher IL-27 levels in the CSF are not positively
but on the contrary possibly negatively correlated
with higher EDSS scores support this hypothesis. IL-
27 levels could be regarded as part of a regulatory re-
sponse held to counterpart the initial inflammation,
but that might however be insufficiently maintained with
disease evolution. An imbalance between inflammatory
and regulatory signals could thus be linked with disease
progression. This hypothesis is supported by the ability of
IFN-β [6] and glatiramer acetate [8], two MS drug-
modifying treatments, to stimulate IL-27 production
which could itself be held as a marker to identify
responders to those treatments [6]. Moreover, the elevated
CSF IL-27 levels can be compared to the increased CSF
IL-10 levels, a recognized anti-inflammatory cytokine,
during RRMS [20]. IL-10 levels are not only increased in
the CSF of MS patients compared to healthy subjects but
also higher at an active stage compared to a relieving stage
Fig. 4 IL-27 expression in MS plaques. a A chronic active lesion of a MS patient autopsy was stained for IL-27 using anti-EBI3 antibody visualized with
DAB. The dashed line indicates the lesion border. b Enlarged detail crop from square region in a. c Representative fluorescence immunohistochemistry
image of a biopsy showing an early active MS lesions co-immunostained for EBI3 (green) and astrocytes (GFAP, red). Nuclei were counterstained using
DAPI (blue). Arrowheads in the merged image indicate EBI3, GFAP double positive cells. Scale bars: a = 200 μm; b = 40 μm; c = 100 μm
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Fig. 3 IL-27 levels are similar in sera of healthy controls and RRMS
patients. Sera were obtained from aged-matched healthy controls
(HC) and patients with RRMS without treatment (untreated) or
treated with interferon beta1a (INF-β1a), glatiramer acetate (GA), or
natalizumab (NTZ)
Table 3 Description of cerebral biopsies
Samples Gender Age [years] DD [years] Lesion type Pattern
MS-1 W 52.69 12.74 EA II
MS-2 W NA NA EA II
MS-3 W 73.17 0.43 EA II
MS-4 M 30.89 0.06 EA II
MS-5 W 35.66 2.89 EA II
MS-6 W 54.69 8.99 EA II
W women, M men, NA not available, EA early active lesion
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in MS patients [21], comforting the idea that the develop-
ment of a regulatory response is present at early stages
during neuroinflammation.
IL-27 is composed of two subunits, EBI3 and p28. A
specific ELISA kit detection for IL-27 has been used that
specifically detects the heterodimeric cytokine IL-27, but
an antibody specific only for EBI3 was used for histology.
While p28 is specific for IL-27, the EBI3 combined p35
composes IL-35 cytokine. We however believe that EBI3
staining is representative of IL-27 cytokine as it is typically
produced by antigen-presenting cells (APCs) [22] while
IL-35 is produced by lymphocytes, in particular Foxp3+
regulatory T-cells [23, 24] and regulatory B-cells [25]. In
the CNS, we observed EBI3 expression in astrocytes but
not in lymphocytes in MS plaques thus supporting our
interpretation that IL-27 but not IL-35 is produced by
astrocytes in the context of MS disease. In one of the six
biopsies, we did not detect EBI3. This could indicate that
EBI3 might not be uniformly expressed within the pla-
ques. Alternatively, the detected epitope of EBI3 might
be vulnerable to tissue fixation-related effects resulting
in antigen masking that prevents antibody binding on
paraffin-embedded tissue as used for this study; over-
fixation might indeed lower epitope recognition by
2G4H6 mAb. Further studies are thus needed to cor-
roborate our histological findings.
IL-27 has anti-inflammatory properties during auto-
immune diseases. We propose that local production of
IL-27 by astrocytes highlights the induction of a regula-
tory response that promotes inflammation’s resolution
that is the hallmark of early MS lesions. Lymphocytes, in
particular infiltrating CD4+ T cells express highest levels
of IL-27 receptor in the CNS, in a EAE mouse model
[10] and in post-mortem tissue analysis [12] suggesting
that IL-27 produced locally at the site of inflammation
may regulate T cell responses during neuroinflammation.
Conclusions
Our study provides additional evidence that IL-27 may
contribute to autoimmune processes in MS patients.
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